Skip to main content
HEM Pharma Inc. logo

HEM Pharma Inc. — Investor Relations & Filings

Ticker · 376270 ISIN · KR7376270005 KO Manufacturing
Filings indexed 93 across all filing types
Latest filing 2022-04-08 Audit Report / Informat…
Country KR South Korea
Listing KO 376270

About HEM Pharma Inc.

https://hempharma.bio/

HEM Pharma Inc. is a biotechnology company specializing in microbiome-based healthcare solutions. The company researches and develops Live Biotherapeutic Products (LBPs), health functional foods, and other bio-products derived from human-effective microbes. A core component of its R&D is the proprietary Pharmaceutical Meta-Analysis System (PMAS), a technology platform that simulates the human gut microbiome to screen for and analyze beneficial microorganisms. In addition to its product pipeline, HEM Pharma provides personalized healthcare services based on microbiome analysis and offers Contract Development and Manufacturing Organization (CDMO) services for next-generation biological materials.

Recent filings

Filing Released Lang Actions
사업보고서 (2021.12)
Audit Report / Information Classification · 1% confidence The document is a formal 'Audit Report' (감사보고서) for HEM Pharma (주식회사 에이치이엠파마) for the fiscal year ending December 31, 2021. It includes the independent auditor's report from Samil PricewaterhouseCoopers, the financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. This is a comprehensive financial audit document, not an announcement or a summary, fitting the 'Audit Report' category. FY 2021
2022-04-08 Korean
감사보고서 (2021.12)
Audit Report / Information Classification · 1% confidence The document is a formal 'Audit Report' (감사보고서) for HEM Pharma (주식회사 에이치이엠파마) for the fiscal year ending December 31, 2021. It includes the independent auditor's report from Samil PricewaterhouseCoopers, the financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. This is a comprehensive financial audit document, not an announcement or a summary, fitting the 'Audit Report' category. FY 2021
2022-04-04 Korean
감사보고서 (2020.12)
Audit Report / Information Classification · 1% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'HEM Pharma' (주식회사 에이치이엠파마). It includes the independent auditor's report, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. It is not an Annual Report (10-K) as it focuses specifically on the audit results and financial statements rather than the broader company activity report. Therefore, it is classified as an Audit Report. FY 2020
2021-05-12 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.